Literature DB >> 10698744

Epitopes involved in antibody-mediated protection from Ebola virus.

J A Wilson1, M Hevey, R Bakken, S Guest, M Bray, A L Schmaljohn, M K Hart.   

Abstract

To determine the ability of antibodies to provide protection from Ebola viruses, monoclonal antibodies (mAbs) to the Ebola glycoprotein were generated and evaluated for efficacy. We identified several protective mAbs directed toward five unique epitopes on Ebola glycoprotein. One of the epitopes is conserved among all Ebola viruses that are known to be pathogenic for humans. Some protective mAbs were also effective therapeutically when administered to mice 2 days after exposure to lethal Ebola virus. The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698744     DOI: 10.1126/science.287.5458.1664

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  229 in total

1.  Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.

Authors:  J A Wilson; M K Hart
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture.

Authors:  Gabriele Neumann; Heinz Feldmann; Shinji Watanabe; Igor Lukashevich; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Ebola virus VP40-induced particle formation and association with the lipid bilayer.

Authors:  L D Jasenosky; G Neumann; I Lukashevich; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.

Authors:  J Brian Kimble; Delphine C Malherbe; Michelle Meyer; Bronwyn M Gunn; Marcus M Karim; Philipp A Ilinykh; Mathieu Iampietro; Khaled S Mohamed; Surendra Negi; Pavlo Gilchuk; Kai Huang; Yuri I Wolf; Werner Braun; James E Crowe; Galit Alter; Alexander Bukreyev
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

6.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

7.  A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.

Authors:  Waranyoo Phoolcharoen; John M Dye; Jacquelyn Kilbourne; Khanrat Piensook; William D Pratt; Charles J Arntzen; Qiang Chen; Hugh S Mason; Melissa M Herbst-Kralovetz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

8.  Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins.

Authors:  Wu Ou; Josie Delisle; Krishnamurthy Konduru; Steven Bradfute; Sheli R Radoshitzky; Cary Retterer; Krishna Kota; Sina Bavari; Jens H Kuhn; Peter B Jahrling; Gerardo Kaplan; Carolyn A Wilson
Journal:  J Virol Methods       Date:  2011-04-13       Impact factor: 2.014

9.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Monoclonal antibody 667 recognizes the variable region A motif of the ecotropic retrovirus CasBrE envelope glycoprotein and inhibits Env binding to the viral receptor.

Authors:  Hanna Dreja; Laurent Gros; Sylvie Villard; Estanislao Bachrach; Anna Oates; Claude Granier; Thierry Chardes; Jean-Claude Mani; Marc Piechaczyk; Mireia Pelegrin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.